title: Long-term cefuroxime axetil in subacute cutaneous lupus erythematosus. A report of three cases.
abstract: BACKGROUND
  Subacute cutaneous lupus erythematosus (SCLE) is a subset of lupus erythematosus characterized mainly by prominent photoaggravated cutaneous manifestations. Standard therapies for SCLE include topical or systemic steroids and antimalarial drugs. Both methods show limited efficacy in clearing cutaneous lesions and occasionally produce serious side effects.
  
  
  OBJECTIVE
  To assess the efficacy of cefuroxime axetil, an oral cephalosporin with antibacterial and immunosuppressive activity, in patients with SCLE.
  
  
  METHODS
  Three patients with SCLE were treated with cefuroxime axetil at a daily dose of 500 mg for 30-60 days.
  
  
  RESULTS
  In all patients complete clearing of skin lesions was achieved and no side effects were observed.
  
  
  CONCLUSIONS
  We suggest that long-term cefuroxime axetil administration might be an alternative treatment for patients with SCLE skin lesions.
authors.affiliation: Department of Dermatology, CSK MSWiA, Warsaw, Poland. lidiarud@czsz.mswia.gov.pl
authors.forename: L
authors.initials: L
authors.lastname: Rudnicka
authors.forename: E
authors.initials: E
authors.lastname: Szymańska
authors.forename: I
authors.initials: I
authors.lastname: Walecka
authors.forename: M
authors.initials: M
authors.lastname: Słowińska
mesh_terms: D000328:Adult; D002444:Cefuroxime / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D012867:Skin / Q000473:pathology
chemical_list: D002511:Cephalosporins; D002444:Cefuroxime; C040738:cefuroxime axetil